←
Kate Morgan574 posts
Kate Morgan avatar

Kate Morgan

@KateEMor_

co-Chief Exec at Myeloma Patients Europe. Interest in health policy and medicines access plus the occasional tweet about Scotland and travel. Views mine.

◷ Joined December 2013▧ 45 Photos and videos
European Hematology Association avatar
⟳ Kate Morgan retweeted
European Hematology Association@EHA_Hematology·Jul 28

🤝 EHA connects hematologists to the EU policy and regulatory domain, and ensures that their needs are conveyed to decisionmakers, at the right time. The patient perspective is an important part of our message. 🔎 Curious to learn more? Read the interview with Kate Morgan, Co-CEO of @MyelomaEurope and a member of EHA’s European Affairs Committee and Patient Advocacy Committee. 🔗eha.fyi/int-kate-morgan #EHAadvocacy #EuropeanAffairsExplained #patientadvocacy

Post attachment
Myeloma Patients Europe avatar
⟳ Kate Morgan retweeted
Myeloma Patients Europe@MyelomaEurope·Jun 14

MPE board member Snezana talks on #myeloma access in Central and Eastern Europe. “Drugs and healthcare are often looked as a cost and not an investment, which is the wrong way around - it is important for advocates to point this out to policymakers. There is a cost of inaction.”

Post attachmentPost attachment
Myeloma Patients Europe avatar
⟳ Kate Morgan retweeted
Myeloma Patients Europe@MyelomaEurope·27 Mar 2025

We asked patients, carers, clinicians, researchers and stakeholders about the biggest challenges in #myeloma and how MPE can make a difference. Their insights helped shape our new Strategic Goals 2025 – 2030. These will drive our work in the coming years. mpeurope.org/about-mpe/our-g…

1:45
Myeloma Patients Europe avatar
⟳ Kate Morgan retweeted
Myeloma Patients Europe@MyelomaEurope·20 Apr 2024

MPE Co-CEO, Katie Joyner, spoke at @EMN_EuMMnet's 5th annual meeting, highlighting the importance of empowering European patients to access clinical trial information. ¨Patients deserve accurate, comprehensive information for informed discussions with healthcare teams.¨

Post attachmentPost attachment
Bruno Paiva avatar
⟳ Kate Morgan retweeted
Bruno Paiva@BrunoPaiva_UNAV·12 Apr 2024

ODAC unanimously votes in favor of using #MRD as an early endpoint for accelerated approval in #myeloma trials This was a huge team effort for more than 8 years and with the generosity of unprecedented data sharing from many investigators around the world. Thank you all! #mmsm

Post attachment
Myeloma Patients Europe avatar
⟳ Kate Morgan retweeted
Myeloma Patients Europe@MyelomaEurope·13 Apr 2024

@US_FDA's Oncologic Drugs Advisory Committee (ODAC) recognises Minimal Residual Disease (MRD) as an accepted endpoint for accelerated approval in myeloma. Read more information here: onclive.com/view/fda-s-odac-… @OncLive #myeloma #MRD

Multiple Myeloma RF avatar
⟳ Kate Morgan retweeted
Multiple Myeloma RF@theMMRF·12 Apr 2024

Today, US FDA held an ODAC meeting to debate MRD as an endpoint to support accelerated approval in #myeloma clinical trials. Two groups (@SylvesterCancer and i2TEAMM) presented retrospective data from clinical trials that measured MRD. Final vote was 12-0 in favor.

Myeloma Patients Europe avatar
⟳ Kate Morgan retweeted
Myeloma Patients Europe@MyelomaEurope·31 Jan 2024

Commissioner @SKyriakidesEU highlights #EUCancerPlan progress, including the first EU network linking National Comprehensive Cancer Centres in every MS, but discussions show more work remains to tackle inequalities, among other issues. #WorldCancerDay

Thank you to everyone who joined our #WorldCancerDay event.   We heard powerful voices, inspiring stories, and a determination to join forces to tackle cancer.   Let us continue to work hand in hand to make this difference, for our friends, our families, for all. #EUCancerPlan

Post attachmentPost attachmentPost attachmentPost attachment
Myeloma Patients Europe avatar
⟳ Kate Morgan retweeted
Myeloma Patients Europe@MyelomaEurope·18 Jan 2024

EU funded project @ASCERTAIN_EU , of which MPE is a partner, is in its second year! The Consortium meeting ended yesterday with presentations on the project’s progress, followed by discussions and suggestions from partners and advisory board members access2meds.eu/about-ascerta…

Kicking off the new year🚀➡ASCERTAIN's third consortium meeting on January 16th and 17th📸Consortium members, stakeholders and Advisory Board representatives worked together to shape our path for the year. #healthtech #accessibility

Post attachment
Myeloma Patients Europe avatar
⟳ Kate Morgan retweeted
Myeloma Patients Europe@MyelomaEurope·18 Dec 2023

Led by @EHA_hematology, with the involvement of MPE, the article "Guidelines for the Use and Reporting of Patient-Reported Outcomes in Multiple Myeloma Clinical Trials" is now published! An important step in improving the collection of #PROs. mdpi.com/2072-6694/15/24/576…

Myeloma Patients Europe avatar
⟳ Kate Morgan retweeted
Myeloma Patients Europe@MyelomaEurope·13 Dec 2023

MPE is a partner in an exciting new @HorizonEU project called #CERTAINTY, which explores the role of virtual twins in CAR-T and personalised #myeloma care. You can explore further information about the project here:

#FraunhoferIZI launches #CERTAINTY with partners, pioneering #VirtualTwin for personalised cancer care. Focused on multiple myeloma, backed by €10M EU, this collaboration is set to transform CAR-T therapy & precision medicine. 👉 izi.fraunhofer.de/en/press/p… #InnovativeOncology

Post attachment